Patent US4491634A successfully refreshed from Google Patents.
US4491634A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Chemiluminescent immunoassay with activator of hydrogen peroxide and a chloramine
Assignee: Individual
•
Filing: 1981-12-22
•
Granted: 1985-01-01
•
Expires: 2001-12-22
Abstract
Abstract In a process for qualitative and quantitative determination of antigens, antibodies, and antigen/antibody complexes, using a chemiluminescent marker in a liquid-phase or solid-phase assay the combination of chemiluminescent marker and activator for the marker is selected from the combinations (a) H 2 O 2 /chloramine (or functionally equivalent derivative) - fluorescein, methylene blue, thionine or functionally equivalent derivatives of these chemiluminescent markers; and (b) calcium hypochlorite-fluorescein or functionally equivalent derivative. The method is simpler and more sensitive than known methods and presents less danger to those performing the assay.
Inventors
- 👤 Bernd Frenzel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 20:15
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/58; G01N33/582; Y; Y10; Y10S; Y10S436/00; Y10S436/80; Y10S436/82
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
107 words
A process for qualitative and quantitative analysis of an immunological reagent selected from the group consisting of antigens, antibodies and antigen-antibody complexes comprising: (a) binding to said immunological reagent a chemiluminescent conjugate comprising an antibody, antigen, or binding protein capable of binding to said immunological reagent which is attached to a chemiluminescent marker selected from the group consisting of fluorescein, methylene blue, thionine and functionally equivalent derivatives of these markers, (b) contacting said bound chemiluminescent marker with an activator selected from the group consisting of mixtures of hydrogen peroxide and chloramine or functionally equivalent derivative of chloramine, (c) measuring the light emitted by said activated chemiluminescent marker.
Claim 2
Dependent Claim
107 words
A process for qualitative and quantitative analysis of an immunological reagent selected from the group consisting of antigens, antibodies and antigen-antibody complexes comprising: (a) binding to said immunological reagent a chemiluminescent conjugate comprising an antibody, antigen, or binding protein capable of binding to said immunological reagent which is attached to a chemiluminescent marker selected from the group consisting of fluorescein, methylene blue, thionine and functionally equivalent derivatives of these markers, (b) contacting said bound chemiluminescent marker with an activator selected from the group consisting of mixtures of hydrogen peroxide and chloramine or functionally equivalent derivative of chloramine, (c) measuring the light emitted by said activated chemiluminescent marker.
Claim 3
Dependent Claim
17 words
The process of claim 1 wherein said activator is a mixture of hydrogen peroxide and chloramine T.
Claim 4
Dependent Claim
37 words
The process of claim 2 wherein said activator is a mixture of equal volumes of a 0.5 to 30% by volume aqueous solution of hydrogen peroxide and a 0.1 to 8% by weight solution of chloramine T.
Claim 5
Dependent Claim
18 words
The process of claim 1 or claim 2 wherein said antigen-antibody complex is prepared by a sandwich immunoassay.
Claim 6
Dependent Claim
18 words
The process of claim 1 or claim 2 wherein said contact is carried out in an aqueous medium.
Claim 7
Dependent Claim
16 words
The process of claim 5 wherein said chemiluminescent emission is measured in a basic aqueous medium.
Claim 8
Dependent Claim
27 words
The process of claim 1 or claim 2 wherein said functionally equivalent derivative of fluorescein is selected from the group consisting of fluorescein isothiocyanate and fluorescein isocyanate.
Claim 9
Dependent Claim
28 words
The process of claim 1 or claim 2 wherein said immunological reagent is selected from the group consisting of hepatitis B antigen and antibodies against herpesvirus or togavirus.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-01 | 1988-07-02 | 1989-01-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-01 | 1992-07-02 | 1993-01-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-01 | 1996-07-02 | 1997-01-01 | $7700.00 | Window Closed / Lapsed |